Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients (EVOLVE) "EVOLVE"


Phase N/A Results N/A

Summary of Purpose

This study will evaluate the next generation WATCHMAN Left Atrial Appendage (LAA) Closure Device as implanted in patients with non-valvular atrial fibrillation (AF) with a CHADS2 stroke risk stratification score of 1 or greater. This is a prospective, non-randomized study to evaluate the initial use of the next generation WATCHMAN Device.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 7 December 2015.

1 May 2009 16 Aug 2010 1 Sep 2012 1 Nov 2013 1 Aug 2012 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Single Group Assignment


Not available